Home Prescribing Information         Patient Information         Important Safety Information        Consumer Site   
Clinical Information
ED & High Cholesterol
ED & High Blood Pressure
Treatment Toolkit
 
LEVITRA® (Vardenafil HCl)
ED & Diabetes
For Your ED Patients With Diabetes, LEVITRA May Be the Answer
LEVITRA significantly improves erectile function in men with diabetes, including erection hardness and successful intercourse completion.8
 
In a study of men with ED and diabetes8
Mean overall reliability of insertion (SEP2) by dose over 12 weeks
 
ED & Diabetes
 
 
In a recent study of men with ED, including those with diabetes18
 
 
Men with ED & Diabetes
 

ED is prevalent among your patients with diabetes. In a cross-sectional evaluation of 1460 with type 2 diabetes, 58% reported having frequent or occasional ED.5

For men over age 50, increasing duration of type 2 diabetes is associated with increased risk of ED relative to nondiabetic men.4 The risk of ED was approximately three times higher for middle-aged and older men with type 1 diabetes than for nondiabetics of similar age.4

Historically, diabetic men have not responded as well to ED treatments. A study shows that vardenafil HCl significantly improved erectile function in diabetic men, even those with severe ED, irrespective of glycemic control (HbA1c ≤12%).8

 
Important Safety and Dosing Information

LEVITRA (vardenafil HCl) is a prescription medicine that is indicated to treat erectile dysfunction (ED). Consistent with the effects of PDE5 inhibition, administration of LEVITRA with nitrates and nitric oxide donors is contraindicated.

Caution is advised when PDE5 inhibitors, including LEVITRA, are used concomitantly with stable alpha-blocker therapy, because of the potential for lowering blood pressure.

LEVITRA is not recommended for patients with uncontrolled hypertension (>170/110 mmHg).

In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used.

In patients taking certain CYP3A4 inhibitors (eg, ritonavir, indinavir, saquinavir, atazanavir, ketoconazole, itraconazole, erythromycin, and clarithromycin), lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended. See prescribing information for LEVITRA for dosing guidance.

In clinical trials, the most commonly reported adverse events with LEVITRA were headache, flushing, and rhinitis. Adverse events were generally transient.

Nonarteritic anterior ischemic optic neuropathy (NAION), has been reported rarely postmarketing in temporal relationship with the use of PDE5 inhibitors, including LEVITRA. Sudden loss of hearing, sometimes with tinnitus and dizziness, also has been reported rarely in temporal association with the use of PDE5 inhibitors, including LEVITRA. It is not possible to determine if these events are related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden loss of vision or hearing.

The recommended starting dose of LEVITRA is 10 mg. Titrate up to 20 mg or down to 5 mg based on efficacy and side effects.

The maximum recommended dosing frequency is once daily.

LEVITRA is available in 2.5-mg, 5-mg, 10-mg and 20-mg tablets.

Please see complete Prescribing Information for 2.5-mg, 5-mg, 10-mg, and 20-mg LEVITRA.
[Requires Adobe® Reader® - click here to download].

   Adobe is a registered trademark of Adobe Systems Incorporated.

This site is intended for US healthcare professionals only.

© 2004-2008 Bayer Pharmaceuticals Corporation. All Rights Reserved. GlaxoSmithKline and Schering Corporation.



Legal Notices | Privacy Statement | Contact Us | Site Map | Search | References

Bayer HealthCare Pharmaceuticals GlaxoSmithKline Schering-Plough